# US 7,745,137 B2 · Method of diagnosing risk of myocardial infarction by detection of specific gene polymorphisms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,137 B2
- Document ID: US7745137B2
- Status: Granted
- Kind: B2
- Application number: 12/382,028
- Filed: 2009-03-06
- Published: 2009-09-24
- Granted: 2010-06-29
- Earliest claimed: 2004-12-21
- Assignees: Nagoya Industrial Science Research Institute
- Inventors: Yoshiji Yamada; Mitsuhiro Yokota
- Web page: https://patentgrep.com/patent/US7745137B2

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

It is intended to provide a means of diagnosing myocardial infarction which shows a high accuracy and a high predictability. The risk of myocardial infarction is diagnosed by a method comprising the following steps: (i) the step of analyzing 2 or more polymorphisms among 10 gene polymorphisms or 5 gene polymorphisms proved as relating to myocardial infarction; (ii) the step of determining the genotype of a nucleic acid sample based on the polymorphism data obtained in the above step; and (iii) the step of determining the genetic risk of myocardial infarction from the genotype thus obtained.

## Claims

### Claim 1

A method for diagnosing the risk of myocardial infarction, comprising the following steps (i) to (iii):
(i) analyzing two polymorphisms (1) and (2) in a nucleic acid sample:
(1) polymorphism at the base number position −1171 of the stromelysin 1 gene; and
(2) polymorphism at the base number position −668 of the plasminogen activator inhibitor-1 gene;
(ii) determining, based on the information about said polymorphism which was obtained in the step (i), the genotype of the nucleic acid sample; and
(iii) assessing, based on the genotype determined, a genetic risk of myocardial infarction.

### Claim 2 (depends on 1)

The method for diagnosing the risk of myocardial infarction according to claim 1, wherein a polymorphism (3) in said nucleic acid sample is additionally analyzed in step (i):
(3) polymorphism at the base number position 4070 of the apolipoprotein E gene.

### Claim 3 (depends on 1)

The method for diagnosing the risk of myocardial infarction according to claim 1, wherein a polymorphism (4) in said nucleic acid sample is additionally analyzed in step (i):
(4) polymorphism at the base number position 1018 of the glycoprotein Ibα gene.

### Claim 4 (depends on 1)

The method for diagnosing the risk of myocardial infarction according to claim 1, wherein a polymorphism (5) in said nucleic acid sample is additionally analyzed in step (i):
(5) polymorphism at the base number position 584 of the paraoxonase gene.

### Claim 5 (depends on 1)

The method for diagnosing the risk of myocardial infarction according to claim 1, wherein polymorphisms (3) and (4) in said nucleic acid sample are additionally analyzed in step (i):
(3) polymorphism at the base number position 4070 of the apolipoprotein E gene; and
(4) polymorphism at the base number position 1018 of the glycoprotein Ibα gene.

### Claim 6 (depends on 1)

The method for diagnosing the risk of myocardial infarction according to claim 1, wherein polymorphisms (3), (4) and (5) in said nucleic acid sample are additionally analyzed in step (i):
(3) polymorphism at the base number position 4070 of the apolipoprotein E gene;
(4) polymorphism at the base number position 1018 of the glycoprotein Ibα gene; and
(5) polymorphism at the base number position 584 of the paraoxonase gene.